Bruker Corporation (BIT:1BRKR)
Italy · Delayed Price · Currency is EUR | Market Cap | 5.62B +5.9% |
| Revenue (ttm) | 3.00B +0.4% |
| Net Income | -31.57M |
| EPS | -0.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 18.77 |
| Dividend | 0.09 (0.23%) |
| Ex-Dividend Date | Mar 20, 2026 |
| Volume | n/a |
| Average Volume | 28 |
| Open | 37.66 |
| Previous Close | 37.66 |
| Day's Range | 37.66 - 37.66 |
| 52-Week Range | 25.24 - 46.55 |
| Beta | n/a |
| RSI | 77.61 |
| Earnings Date | May 6, 2026 |
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
News
Bruker price target raised to $45 from $40 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Hold rating on the shares.
Bruker price target raised to $45 from $43 at TD Cowen
TD Cowen raised the firm’s price target on Bruker (BRKR) to $45 from $43 and keeps a Hold rating on the shares. The firm updated its odel following Q1 results…
Bruker price target raised to $45 from $40 at UBS
UBS raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Neutral rating on the shares.
Bruker price target raised to $53 from $45 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Bruker (BRKR) to $53 from $45 and keeps an Overweight rating on the shares.
Bruker price target raised to $44 from $40 at Citi
Citi raised the firm’s price target on Bruker (BRKR) to $44 from $40 and keeps a Neutral rating on the shares.
Bruker reports Q1 adjusted EPS 31c, consensus 23c
Reports Q1 revenue $823.4M, consensus $795.67M. Frank H. Laukien, Bruker’s (BRKR) President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quart...
Bruker backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
06:35 EDT Bruker (BRKR) backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
Bruker Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong bookings in AI-driven and security segments, despite U.S. academic and currency headwinds. Guidance for FY2026 is reaffirmed, with margin expansion and EPS growth driven by cost savings and innovation momentum.
Bruker Reports First Quarter 2026 Financial Results
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President a...
Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026...
Bruker to showcase updates from Bruker Spatial Biology at AACR meeting
Bruker (BRKR) Corporation announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research Annual Meeting. At AACR, Bruker Spatial Biology will hi...
Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Resear...
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PR...
Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequenc...
Bruker price target lowered to $45 from $50 at Barclays
Barclays lowered the firm’s price target on Bruker (BRKR) to $45 from $50 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and…
Bruker unveils NMR products, workflow solutions at ENC 2026
At the Experimental Nuclear Magnetic Resonance Conference, Bruker (BRKR) Corporation announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation acros...
Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
ASILOMAR, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (Nasdaq: BRKR) today announced new NMR products and workflow solu...
Bruker invests in photothermal AFM-IR to advance semiconductor research
Bruker (BRKR) announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges facing the semiconductor industry as device architectures continue t...
Bruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research ch...
Bruker appoints Bernard to its Board of Directors
Bruker Corporation (BRKR) announces the appointment of Thierry Bernard to serve on its Board of Directors, effective as of today. Bernard currently serves as Chief Executive Officer of QIAGEN (QGEN).
Bruker Announces Appointment of Thierry Bernard to its Board of Directors
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. ...
Bruker price target lowered to $50 from $58 at Guggenheim
Guggenheim lowered the firm’s price target on Bruker (BRKR) to $50 from $58 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
PTAB upholds Seer patent for nano- and microparticles in challenge by Bruker
Seer (SEER) announced that the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23 in an inter…
Rising helium prices could create headwind for Bruker, says Jefferies
Jefferies analyst Tycho Peterson notes headlines surfaced last week around helium price shocks amid the escalating conflict in the Middle East, where 20% of the globe’s helium supply is sourced,…
Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR
ORLANDO, Fla.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the developme...